NEW YORK (GenomeWeb News) – Transgenomic today announced it has received confirmation of Medicare coverage for its clopidogrel response test.

National Government Services, the Medicare fiscal intermediary for Connecticut, has confirmed coverage for Transgenomic's Clopidogrel Genetic Absorption Activation Panel, or C-GAAP, providing 48 million Americans currently on Medicare access to the test, formerly called PGxPredict: Clopidogrel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.